Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.

Abstract

BACKGROUND AND OBJECTIVE:

Few treatment options exist for patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) who fail first- and second-line therapies. Pixantrone is a novel aza-anthracenedione agent with reduced potential for cardiotoxicity but maintained anti-tumour activity relative to anthracyclines. The current retrospective, observational, real-life study was undertaken in 79 patients who received pixantrone monotherapy for multiply R/R aggressive B-cell NHL in Spain and Italy.

RESULTS:

Before pixantrone, patients had received a median of 3 prior therapies and 84.6% of them were refractory to the last regimen. Median progression-free survival (mPFS) was 2.8 months (95% confidence interval [CI] 2.1-3.6) and median overall survival (mOS) was 4.0 months (95%CI 5.6-7.9), with an objective response rate (ORR) of 29% (complete remission [CR]: 13.2%, partial remission [PR]: 15.2%). Patients receiving ≥2 cycles of pixantrone showed mPFS and mOS of 3.1 and 6.0 months, respectively, and an ORR of 36.8% (CR: 17.5%, PR: 19.3%). Overall, 63.3% of patients reported ≥1 adverse event (AE), most commonly haematological AEs. One patient developed grade 2 sinus tachycardia.

CONCLUSION:

Pixantrone was effective and well tolerated in a real-world population of multiply R/R patients with aggressive B-cell NHL, many of whom had very poor prognostic factors.

• Authors: Juan-Manuel Sancho, Belén Navarro, Joan Alfons Soler Campos, Jaime Pérez de Oteyza, Cristina de Barrenetxea Lekue, Marco Bregni, Silvina Grasso Cicala, Mario Spione, Cristina Mombiedro, Begoña Soler, Pier Luigi Zinzani
• Journal: European journal of haematology (Eur J Haematol) Vol. 104 Issue 5 Pg. 499-508 (May 2020) ISSN: 1600-0609 [Electronic] England
• PMID: 31997425 (Publication Type: Journal Article)
• Copyright: © 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Chemical References

• Antineoplastic Agents
• Isoquinolines
• Topoisomerase II Inhibitors
• pixantrone

Topics

• Aged
• Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
• Drug Resistance, Neoplasm
• Female
• Humans
• Isoquinolines (administration & dosage, adverse effects, therapeutic use)
• Kaplan-Meier Estimate
• Lymphoma, Non-Hodgkin (drug therapy, mortality, pathology)
• Male
• Middle Aged
• Neoplasm Staging
• Prognosis
• Recurrence
• Retreatment
• Retrospective Studies
• Topoisomerase II Inhibitors (administration & dosage, adverse effects, therapeutic use)
• Treatment Outcome